Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Dividends payables (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Dividends payables for 4 consecutive years, with $32491.0 as the latest value for Q1 2026.

  • Quarterly Dividends payables changed N/A to $32491.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $32491.0 through Jan 2026, changed N/A year-over-year, with the annual reading at $6.3 million for FY2024, N/A changed from the prior year.
  • Dividends payables for Q1 2026 was $32491.0 at PharmaCyte Biotech, down from $35389.0 in the prior quarter.
  • The five-year high for Dividends payables was $6.3 million in Q2 2024, with the low at $32491.0 in Q1 2026.
  • Average Dividends payables over 4 years is $3.4 million, with a median of $3.9 million recorded in 2023.
  • The sharpest move saw Dividends payables skyrocketed 1849.31% in 2024, then tumbled 99.05% in 2025.
  • Over 4 years, Dividends payables stood at $4.1 million in 2023, then dropped by 9.15% to $3.7 million in 2024, then crashed by 99.05% to $35389.0 in 2025, then decreased by 8.19% to $32491.0 in 2026.
  • According to Business Quant data, Dividends payables over the past three periods came in at $32491.0, $35389.0, and $3.7 million for Q1 2026, Q4 2025, and Q4 2024 respectively.